<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APOC1 Gene — Apolipoprotein C-I</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>APOC1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Apolipoprotein C-I</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.32</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>341</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>107710</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000130208</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02654</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>79 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~9 kDa</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Band</td>
<td>q13.32</td>
</tr>
<tr>
<td class="label">Strand</td>
<td>Minus strand</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>4</td>
</tr>
<tr>
<td class="label">Transcript length</td>
<td>~1.2 kb coding region</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>TATA-less, GC-rich</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Identity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APOC1 Gene — Apolipoprotein C-I</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>APOC1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Apolipoprotein C-I</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.32</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>341</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>107710</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000130208</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02654</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>79 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~9 kDa</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Band</td>
<td>q13.32</td>
</tr>
<tr>
<td class="label">Strand</td>
<td>Minus strand</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>4</td>
</tr>
<tr>
<td class="label">Transcript length</td>
<td>~1.2 kb coding region</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>TATA-less, GC-rich</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Identity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>73%</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>72%</td>
</tr>
<tr>
<td class="label">Bovine</td>
<td>86%</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>48%</td>
</tr>
<tr>
<td class="label">Isoelectric point</td>
<td>7.9</td>
</tr>
<tr>
<td class="label">Hydrophobicity</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lipid binding</td>
<td>High affinity for HDL</td>
</tr>
<tr>
<td class="label">Dimerization</td>
<td>Can form dimers</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~15 hours in plasma</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">APOC1*2</td>
<td>Increased AD risk (OR ~2-3)</td>
</tr>
<tr>
<td class="label">APOC1 ε4 interaction</td>
<td>Synergistic risk</td>
</tr>
<tr>
<td class="label">APOC1 promoter variants</td>
<td>Altered expression</td>
</tr>
<tr>
<td class="label">Haplotype effects</td>
<td>Differential risk</td>
</tr>
<tr>
<td class="label">Association</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Elevated triglycerides</td>
<td>Lipoprotein lipase inhibition</td>
</tr>
<tr>
<td class="label">Atherosclerosis</td>
<td>Triglyceride-rich lipoprotein effects</td>
</tr>
<tr>
<td class="label">Coronary artery disease</td>
<td>Lipid-mediated vascular effects</td>
</tr>
<tr>
<td class="label">Metabolic syndrome</td>
<td>Insulin resistance association</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ApoC-I inhibitors</td>
<td>Reduce triglyceride levels</td>
</tr>
<tr>
<td class="label">Monoclonal antibodies</td>
<td>Neutralize apoC-I</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>Reduce APOC1 expression</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>RNAi approaches</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Modulate function</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Phenotype</td>
</tr>
<tr>
<td class="label">APOC1 transgenic</td>
<td>Elevated plasma apoC-I</td>
</tr>
<tr>
<td class="label">APOC1 knockout</td>
<td>Reduced triglycerides</td>
</tr>
<tr>
<td class="label">ApoE/APOC1 double</td>
<td>Synergistic effects</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Lipid metabolism</td>
<td>Direct role</td>
</tr>
<tr>
<td class="label">LDL receptor pathway</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">HDL metabolism</td>
<td>Exchange</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">APOC1 genotype</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">ApoC-I protein</td>
<td>Plasma/CSF</td>
</tr>
<tr>
<td class="label">Expression levels</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Apolipoprotein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">APOA1</td>
<td>HDL formation</td>
</tr>
<tr>
<td class="label">APOC1</td>
<td>LPL inhibition</td>
</tr>
<tr>
<td class="label">APOC2</td>
<td>LPL activation</td>
</tr>
<tr>
<td class="label">APOC3</td>
<td>LPL inhibition</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Lipid transport</td>
</tr>
<tr>
<td class="label">APOJ</td>
<td>Aβ binding</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Genotyping</td>
<td>Genetic variants</td>
</tr>
<tr>
<td class="label">ELISA</td>
<td>Protein levels</td>
</tr>
<tr>
<td class="label">qPCR</td>
<td>mRNA expression</td>
</tr>
<tr>
<td class="label">Immunohistochemistry</td>
<td>Tissue localization</td>
</tr>
<tr>
<td class="label">Mass spectrometry</td>
<td>Post-translational modifications</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>
APOC1 encodes apolipoprotein C-I (apoC-I), a 79-amino acid lipoprotein that plays critical roles in lipid metabolism and has emerged as a significant genetic risk factor for [Alzheimer's disease](/diseases/alzheimers-disease). Located within the apolipoprotein gene cluster on chromosome 19q13.32, alongside [APOE](/genes/apoe) and APOC2, APOC1 has been associated with increased susceptibility to Alzheimer's disease through multiple genetic epidemiological studies[@lane2013][@beresniak2012]. The protein is expressed primarily in the liver and intestine, with lower expression detected in [neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes) within the brain[@cheng2017][@zhang2019].
The connection between APOC1 and neurodegeneration represents an important intersection of lipid metabolism and brain health. Given the growing evidence linking lipid dysregulation to Alzheimer's disease pathogenesis, APOC1 represents both a risk factor and potential therapeutic target for intervention.
The APOC1 gene spans approximately 4.7 kb on chromosome 19q13.32 within the apolipoprotein gene cluster. This genomic region represents a conserved haplotype block that includes APOE, APOC1, and APOC2, all of which are involved in lipid metabolism regulation[@wang2015].
Apolipoprotein C-I is conserved among mammals with functional significance:
ApoC-I demonstrates a distinctive expression pattern across tissues:
High expression:
ApoC-I is a small apolipoprotein with distinct structural features:
ApoC-I demonstrates several key biochemical properties:
The protein contains multiple lysine and arginine residues in its N-terminal region, facilitating interactions with negatively charged phospholipids on lipoprotein surfaces.
ApoC-I plays multiple roles in systemic lipid metabolism[@yu2020]:
Within the brain, apoC-I has emerging functions[@zhang2019][@cheng2017]:
APOC1 has been consistently associated with Alzheimer's disease risk through genetic studies[@lane2013][@beresniak2012]:
Several mechanisms link APOC1 to Alzheimer's disease[@kim2018][@song2019]:
The APOC1 gene sits in tight linkage disequilibrium with APOE, creating complex genetic effects[@poduslo1999][@scarmeas2005]:
Beyond neurodegenerative diseases, APOC1 affects cardiovascular health[@tansley2022]:
ApoC-I represents a potential therapeutic target[@liu2021]:
While no trials specifically target APOC1 in neurodegeneration:
The following diagram shows the key molecular relationships involving APOC1 Gene — Apolipoprotein C-I discovered through SciDEX knowledge graph analysis: